18 August 2026 Sydney, Australia

Nyrada Full Year Results FY2026

Highlights:

- Xolatryp® Clinical Program
  - First patient dosed (shortly after year-end) in Nyrada's Phase IIa PROTECT-MI clinical trial evaluating the safety and preliminary efficacy of Xolatryp® in reducing cardiac reperfusion injury in heart-attack patients undergoing angioplasty with stenting (PCI).
  - Nepean Hospital (NSW) activated during the year and Sir Charles Gairdner Hospital (WA) activated shortly after year-end; trial on track for completion in 2HCY2027.
  - Full, unblinded Phase I trial results released showing strong safety profile with no serious adverse events, no dose-limiting safety signals, and predictable, linear pharmacokinetics, thereby providing the foundation to move into Phase IIa trial.
- Xolatryp Regulatory and R&D Program
  - Preparation of a US FDA Investigational New Drug (IND) application commenced for the myocardial ischemia reperfusion injury program, with submission targeted before the end of CY2026.
  - Xolatryp demonstrated anti-tumour efficacy and doxorubicin treatment enhancement in preclinical study. Pilot study demonstrated cardioprotection from doxorubicin-induced cardiomyopathy.
- Finance, Capital & Corporate
  - Cash position of AU$8.38 million as at 30 June 2026 (AU$2.93 million at 30 June 2025), fully funding clinical and preclinical programs.
  - AU$8.25 million (before costs) raised via placement in August 2025 to institutional, sophisticated and professional investors at AU$0.300 per CDI.
  - R&D tax rebate of AU$2.45 million received in respect of FY2025 claim. Accrued (estimated) R&D rebate of $1.72 million in respect of FY2026 expected to be received in the quarter ending 31 December 2026.Composition-of-matter patent application published, and Notice of Allowance received from the US Patent Office. Xolatryp® trademark granted.

Nyrada Inc (ASX:NYR), a clinical stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions, today released its 2026 financial year audited accounts and Annual Report.

Nyrada Inc. Level 22/23, Salesforce Tower, 180 George Street, Sydney NSW 2000 ARBN 625 401 818

FY2026 was a transformational year for Nyrada. The Company completed its first-in-human Phase I program and advanced into a Phase IIa clinical trial, now actively recruiting patients. It has also extended its TRPC platform into oncology; and further strengthened its intellectual property position and balance sheet. Nyrada enters FY2027 as a clinical-stage company with a broader pipeline and the funding to advance it.

Xolatryp® Clinical Program

Completing Phase I

Early in the financial year, Nyrada released the complete, unblinded results of its Phase I clinical trial. The Safety Review Committee's review of the final cohort identified no dose-limiting safety signals in participants receiving Xolatryp, and the full dataset confirmed a strong safety profile with no serious adverse events.

Pharmacokinetic analysis showed predictable, linear blood levels over time, with no differences in exposure between sexes. These results provided the confidence and regulatory footing to move directly into patient testing in a Phase IIa setting.

Launching PROTECT-MI Phase IIa Clinical Trial

The centrepiece of FY2026 was the design and launch of Nyrada's Phase IIa trial, PROTECT-MI, which is evaluating Xolatryp in patients who have suffered a heart attack and are undergoing angioplasty with stenting (PCI).

Although safety is the trial's primary endpoint, multiple secondary and exploratory efficacy measures are also being evaluated, including cardiac function, the extent of cardiac injury, biomarkers such as troponin I, and the incidence of arrhythmias.

The trial is a randomised, double-blind and placebo-controlled study, thus efficacy data will not be available until the study concludes and results analysed. This is expected in the second half of the 2027 calendar year.

Nepean Hospital (NSW) was activated late in the financial year, enabling patient recruitment. Sir Charles Gairdner Hospital (WA) was activated shortly following the conclusion of the financial year. Research governance office (RGO) approval for five other sites within Australia is progressing and discussions are also advancing with additional sites across Australia and New Zealand.

The trial remains on track for completion in CY2027, with the final patient expected to be dosed in mid-calendar 2027 and top-line results anticipated approximately three months after last-patient follow-up.

Nyrada will provide regular updates including on recruitment, sites activated, and Safety Review Committee assessments.

Broadening the Pipeline

During the 2026 financial year, Nyrada extended the Xolatryp program into oncology, where its TRPC mechanism has compelling scientific rationale.

In the first of two preclinical studies, Xolatryp demonstrated clear anti-tumour activity in a model of liver cancer, both as a monotherapy and in combination with doxorubicin. The combination of Xolatryp and doxorubicin produced the greatest reduction in tumour volume and was well tolerated.

The second study was a pilot conducted ahead of a larger cardiomyopathy study assessing whether Xolatryp can protect the heart in patients receiving doxorubicin. The pilot study confirmed the feasibility and tolerability of the intended subcutaneous dosing regimen and informed dose selection for a larger cardiomyopathy study.

The dosing phase of this larger study has now been completed. Data is being collated for analysis with results to be disclosed in the coming weeks.

Regulatory Progress

Shortly following the conclusion of the financial year, Nyrada is preparing an investigational new drug (IND) application to submit to the US FDA. A pre-IND meeting with the Agency has been requested with the IND application to be submitted prior to the conclusion of CY2026

Financial and Corporate

Throughout FY2026, Nyrada maintained disciplined capital and cost management while ensuring its clinical and research programs were fully funded.

The year opened on the strength of a AU$8.25 million (before costs) placement completed in August 2025 at AU$0.300 per CDI. During the year, the Company received an R&D tax rebate of AU$2.45 million in respect of its FY2025 claim and benefited from proceeds received on the exercise of options.

Consistent with prior years, Nyrada intends to lodge a claim under the Commonwealth Government's R&D tax Incentive scheme for research conducted in the 2026 financial year, with an expected refund of $1.72 million to be received in the quarter ending 31 December 2025.

As at 30 June 2026, the Company held a cash position of AU$8.38 million (AU$2.93 million at 30 June 2025) and reported a loss after income tax of AU$6.56 million for the year. A full accounting of the Company's financial performance and position is set out in the Directors' Report and financial statements within the FY2026 Annual Report.

Protecting Xolatryp remained a priority throughout the year. The composition-of-matter patent application was published, the Xolatryp® trademark was granted, and the Company received a Notice of Allowance from the US Patent Office late in the financial year.

Subject to payment of the issue fee, the granted patent will secure protection over Xolatryp's chemical structure in the United States for a twenty-year term from the September 2024 priority date.

Board and Governance

In October 2025, Chief Executive Officer James Bonnar was appointed the Board as Managing Director. Following the November 2025 Annual General Meeting, Dr Gisela Mautner retired from the Board.

Outlook

As Nyrada enters FY2027, its priorities are clear:

- advance PROTECT-MI toward conclusion and data read-out;
- lodge its IND with the US FDA; and
- advance is other preclinical programs towards the clinic, further enhancing the value of Xolatryp.

-ENDS-

About Xolatryp®

Xolatryp is a small-molecule inhibitor of TRPC3/6/7 channels designed to limit excessive Ca^{2+} entry related to multiple disease pathologies.

A Phase I clinical trial to assess the safety, tolerability, and pharmacokinetics has been successfully completed and a Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI.

Key Links:

Corporate Presentation - https://bit.ly/4v0QgXE

Foundation Studies

- GLP study results – https://bit.ly/4d8VYkX
- Phase I trial results – https://bit.ly/3Nt0GzH

Cardiac Studies

- Phase IIa PROTECT-MI website - https://www.protect-mi.com
- Phase IIa study fact sheet – https://bit.ly/4bcDlKj
- Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ
- Preclinical cardioprotection study 1b - https://bit.ly/4rmOsXn
- Preclinical cardioprotection study 2 - https://bit.ly/40jHpUg

Oncology Studies

- Preclinical anti-tumour study - https://bit.ly/49rWOa0
- Preclinical cardioprotection pilot study - https://bit.ly/3QS1VKm

Stroke Study

- Preclinical stroke study - https://bit.ly/4sygHmH

TBI Study

- Preclinical TBI study - https://bit.ly/40fhrRT

About Nyrada Inc.

Nyrada Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative small-molecule therapies, specifically targeting Transient Receptor Potential Canonical (TRPC) ion channels. The company's lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection, and oncology models and has completed a first-in-human Phase I clinical trial. A Phase IIa clinical trial has commenced to assess the safety and preliminary efficacy of Xolatryp in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Nyrada Inc. (ARBN 625 401 818) is incorporated in Delaware, US, with limited liability for its stockholders.

www.nyrada.com

Authorised by John Moore, Non-Executive Chair, on behalf of the Board.

Investor & Media Enquiries:
Dimitri Burshtein
T: 0491 789 391
E: info@nyrada.com

Company Secretary:
David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.